InsiderTrades

Form 4 for NBIX NEUROCRINE BIOSCIENCES INC

Accepted 2026-09-10 20:29:07 ET · period of report 2026-09-09 · accession 0001643653-26-000016 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DT 2026-09-10 20:29 2026-09-09 NBIX BENEVICH ERIC Chief Commercial Off M - OptEx $43.24 +3,194 66.6K +5% +$138.1K
DT 2026-09-10 20:29 2026-09-09 NBIX BENEVICH ERIC Chief Commercial Off S - Sale+OE $154.61 -2,154 64.4K -3% -$333.0K
DT 2026-09-10 20:29 2026-09-09 NBIX BENEVICH ERIC Chief Commercial Off M - OptEx $0.00 -3,194 0 -100% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2026-09-09 M A 3,194 $43.24 66,562 D — — (F1) Includes an aggregate of 178 shares purchased on February 27, 2026 and August 31, 2026 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan.
2 Common Common Stock 2026-09-09 S D 2,154 $154.61 64,408 D — — (F2) The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2026. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
3 Derivative Incentive Stock Option 2026-09-09 M D 3,194 $0.00 0 D $43.24 · — to 2027-02-06 3,194 Common Stock (F3) The option was granted February 6, 2017 and vested in 48 equal monthly installments beginning March 6, 2017. These options were due to expire on February 6, 2027.